31st European Hematology Association Congress
(EHA 2026)
Fueled by Connections to Transform Rare Diseases™
Agios at EHA 2026
New data on Agios’ pyruvate kinase (PK) activator, mitapivat, will be featured in oral and poster presentations, including a presentation of detailed RISE UP Phase 3 results in sickle cell disease during the Plenary Abstracts Session. This builds on over a decade of research that has consistently demonstrated the transformative potential of mitapivat as a disease-modifying oral medicine for hemolytic anemias, including sickle cell disease and thalassemia.
In total, 10 presentations and publications led by Agios and external collaborators will be shared at EHA 2026.
Visit the company’s booth (#A1.04) onsite.
Agios EHA 2026 Data Room & Resources
Agios EHA 2026 Data Room
View Agios- and collaborator-led presentations and publications shared at EHA 2026.
Medical & Scientific Resources
Access educational and scientific resources related to Agios’ investigational and approved medicines. This site is for healthcare professionals only.
AQVESME™ (mitapivat)
Learn more about Agios’ FDA-approved PK activator for thalassemia. This site is for U.S. healthcare professionals only.
Rethink Thalassemia
Find out more about the subtypes of thalassemia, its risks and complications, and how to manage the disease. This site is for U.S. healthcare professionals only.
PYRUKYND® (mitapivat)
Learn more about Agios’ FDA-approved PK activator for PK deficiency. This site is for U.S. healthcare professionals only.
Know Pyruvate Kinase (PK) Deficiency
Access information on PK deficiency and how to manage the disease, disease burden, and importance of management. This site is for U.S. healthcare professionals only.
6/26